What Aralez Pharmaceuticals does

Aralez Pharmaceuticals is a global specialty pharmaceutical company founded in 1996, with Canadian operations conducted through its subsidiary Searchlight Pharma Inc. (Montreal, Quebec). The company focuses on the search, acquisition, commercialization, and focused development of innovative branded specialty pharmaceuticals across women's health, dermatology, allergy, neurology, pain management, and hospital specialty markets. Its portfolio spans more than 65 commercial brands, including Nextstellis (a first-in-world combined oral contraceptive based on Estetrol), Addyi (the only Health Canada-approved oral treatment for HSDD), Haloette vaginal contraceptive ring, Evra transdermal contraceptive patch, Suvexx (a fixed-dose naproxen sodium/sumatriptan migraine therapy), and dermatology products TWYNEO and EPSOLAY based on proprietary Sol-Gel silica-based microencapsulation technology. The company also holds the Mona Lisa IUD franchise, Estragyn vaginal cream, Divigel, and Bulkamid, supported by wholly-owned subsidiaries including Aralez Pharmaceuticals Canada Inc. and Nuvo Pharmaceuticals (Ireland) Designated Activity Company for international IP rights.

The business model is a hybrid of branded pharmaceutical commercialization and licensing. Revenue is generated primarily through product sales across Canada via wholesalers and retail pharmacies, supplemented by licensing and royalty income from international partners such as Orion Corporation (which markets Suvexx across all E.U. countries) and Mithra Pharmaceuticals (which developed Nextstellis, Haloette, and DONESTA). The company has pursued a roll-up growth strategy, acquiring ERFA Canada 2012 Inc. in January 2022 and Miravo Healthcare in March 2023 to scale into a top-three Canadian specialty pharma company by IQVIA CDH sales data. In June 2024, Apotex Inc. acquired Searchlight Pharma, making it a wholly-owned subsidiary operating as Apotex's specialty pharmaceutical division. Pricing is regulated through Canadian provincial formularies and public drug plans rather than market-set, and the company markets primarily through a national salesforce targeting healthcare professionals.

Name

Aralez Pharmaceuticals

Legal name

Searchlight Pharma Inc.

Website

https://aralez.com

Company type

Private

Founded year

1996

Operating status

Acquired

Headcount range

51–100 employees

Short description

Aralez Pharmaceuticals is a global specialty pharmaceutical company that acquires, licenses, and commercializes innovative branded specialty drugs across women's health, dermatology, neurology, pain, and hospital specialty markets, serving Canadian and European patients through a 65+ brand portfolio.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industries

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK), Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD), Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

Keywords

• Specialty pharmaceuticals
• Branded pharmaceuticals
• Pharmaceutical commercialization
• Global pharmaceutical products
• Specialty pharma acquisitions

Headquarters

HQ city

Brooklyn

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Supply Chain, Technology or R&D

Revenue model

1. Product Sales: Searchlight generates revenue through the sale of commercialized pharmaceutical products across Canada, including women's health, dermatology, allergy, neurology, pain management, and hospital specialty products. The company markets over 65 brands.
2. Licensing and Royalty Revenue: Searchlight receives milestone payments and royalties from licensing agreements. For example, under the DONESTA agreement, Mithra receives EUR 1.5 million upfront plus EUR 15.55 million in regulatory and sales milestones, plus tiered royalties on Canadian net sales. The Suvexx European agreement generates EUR 600K upfront, EUR 400K on launch, plus sales-based milestones and royalties.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Aralez Pharmaceuticals is a global specialty pharmaceutical company that acquires, develops, and commercializes branded pharmaceutical products across multiple therapeutic areas including women's health, dermatology, neurology, pain management, allergy, and hospital specialty markets. The company raised $350 million in 2015 to support growth initiatives and acquisitions, including the acquisition of Tribute Pharmaceuticals Canada, and operates through its subsidiary Aralez Pharmaceuticals Canada Inc. with a portfolio of over 65 brands.

Product overview

Searchlight Pharma operates as a specialty pharmaceutical company with a diversified portfolio spanning women's health, dermatology, allergy, neurology, pain management, and hospital specialty markets. The company focuses on acquisition, commercialization, and focused development of innovative branded pharmaceuticals. Key products include Nextstellis (combined oral contraceptive with novel Estetrol), Addyi (HSDD treatment), Haloette and Evra (contraceptives), Suvexx (migraine treatment), and Twyneo/Epsolay (dermatology). Following acquisition of Miravo Healthcare in March 2023, the portfolio expanded to include dermatology and pain management products. The company holds over 65 brands across key therapeutic areas and operates as the specialty pharmaceutical division of Apotex.

Differentiator

Problem solved

Functional benefit

Brands

• Suvexx: Patent protected fixed dose combination of naproxen sodium and sumatriptan for acute migraine treatment. Originally developed by POZEN Inc. in collaboration with Glaxo Group Limited. Marketed in Europe by Orion Corporation under license from Nuvo Pharmaceuticals (Ireland) DAC.

Products and services

• Nextstellis Novel combined oral contraceptive containing 15 mg Estetrol (E4) and 3 mg drospirenone in a 24/4 dosing regimen. First new estrogen in a combined oral contraceptive in Canada in over 50 years, indicated for pregnancy prevention.
• Addyi (flibanserin) First and only oral treatment for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Non-hormonal medication indicated for low libido and associated distress.
• Haloette Vaginal contraceptive ring containing etonogestrel and ethinyl estradiol. Non-biodegradable, flexible, transparent ring worn for three weeks with one-week break, indicated for pregnancy prevention.
• Evra Transdermal contraceptive patch worn once weekly for three weeks. Only transdermal contraceptive option in the Canadian market, originally approved by Health Canada in 2002, indicated for pregnancy prevention.
• Suvexx Patent-protected fixed dose combination of naproxen sodium 500mg and sumatriptan 85mg in a single tablet. Acute migraine treatment for adults with or without aura, originally developed by POZEN with GSK technology.
• Mona Lisa IUDs Intrauterine devices for contraception. Market-leading brand in Canadian women's health portfolio.
• Estragyn Vaginal Cream Vaginal cream treatment for vulvar and vaginal atrophy (VVA), part of the women's health portfolio addressing menopausal symptoms.
• Divigel Gel formulation hormone therapy for treatment of menopausal symptoms.
• Bulkamid Treatment for stress urinary incontinence, part of urology/urogynecology portfolio.
• Norlutate Treatment for endometriosis. Part of the ERFA Canada portfolio of over 20 brands.
• Thyroid Treatment for hypothyroidism. Part of the ERFA Canada portfolio of over 20 brands.

Quantifiable outcome

• Three-year revenue growth of 260% (2016-2019)
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Six partnerships are on record, tiered core and major.

• Mithra PharmaceuticalscoreStrategic or Co-development Partner · 26 October 2023Multi-product partnership for women's health products in Canada. Includes DONESTA (menopause treatment, licensing agreement October 2023), NEXTSTELLIS (combined oral contraceptive, approved and launched Q3 2021), and HALOETTE (vaginal contraceptive ring, launched Q1 2022). Mithra to receive up to €17.05 million in licensing fees and milestones plus tiered royalties on Canadian net sales.
• Sol-Gel TechnologiescoreOEM/ Whitelabel/ Licensing Partner · 6 June 2023Exclusive license agreements for TWYNEO (acne treatment) and EPSOLAY (rosacea treatment) for Canadian market over 15-year renewable term. Sol-Gel to receive up to $11 million in upfront and milestone payments plus royalties ranging from low double-digits to high-teens on Canadian net sales.
• Gedeon Richter (Richter)coreChannel Partner/ Reseller/ Distributor · 12 May 2022Searchlight assumed all Canadian distribution and promotional activities for Evra transdermal contraceptive patch. Transition covers regulatory, distribution and promotional responsibilities in Canada following Richter's acquisition of ex-US rights from Janssen/Johnson & Johnson.
• ERFA Canada 2012 Inc.majorStrategic or Co-development Partner · 5 January 2022Acquisition of ERFA Canada 2012 Inc., a Montreal-based distributor of niche pharmaceutical products. Added portfolio of 23 marketed brands across endocrinology, oncology, cardiovascular, antibiotics, analgesics, and antidepressants. Immediately accretive to revenue and EBITDA.
• Orion CorporationcoreChannel Partner/ Reseller/ Distributor · 1 December 2020Exclusive license and supply agreement for Suvexx in Finland, Sweden, Denmark, Norway, Poland, Hungary, Latvia, Lithuania, Estonia (original territory). Expanded in August 2023 to include all remaining E.U. countries. Orion manages marketing authorizations and commercial activities; pays EUR 600K upfront, EUR 400K on launch, plus milestones and royalties.
• Sprout PharmaceuticalscoreOEM/ Whitelabel/ Licensing Partner · 16 September 2020Licensing agreement for Addyi (flibanserin) Canadian commercial rights. Addyi is the first and only Health Canada-approved oral treatment for HSDD in premenopausal women.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Valeo Pharma: Canadian specialty pharmaceutical company commercializing branded products in respiratory, neurology, dermatology, and women's health. Highly comparable business model and therapeutic-area overlap with Searchlight.
• Cipher Pharmaceuticals: Canadian specialty pharma focused on commercializing branded prescription products in dermatology and other specialty areas. Closely comparable in-licensing + niche commercialization model and Canadian commercial focus.
• Knight Therapeutics: Montreal-based Canadian specialty pharmaceutical company that in-licenses, acquires, and commercializes innovative branded pharmaceuticals across Latin America, Canada, and select markets. Mirrors Searchlight's specialty-pharma in-licensing and acquisition model in the same Canadian ecosystem.
• Mithra Pharmaceuticals: Belgian specialty pharma developing women's health products including Nextstellis (E4/DRSP), Haloette (Myring), and DONESTA. Core partner of Searchlight and direct competitor in the same E4-based women's health and contraceptive categories outside Canada.

Broad incumbents

• Organon & Co. Global women's health-focused pharma with a sizable contraceptive, fertility, and menopause portfolio (e.g., Nexplanon, NuvaRing). Direct adjacency in women's health and chosen therapeutic focus of Searchlight.
• Endo International: Global specialty pharma with branded franchises in women's health, dermatology, neurology, and pain management. Therapeutic-area overlap with Searchlight's diversified specialty portfolio across multiple categories.
• Bausch Health Companies: Large Canadian-domiciled specialty pharma with broad portfolio across dermatology, neurology, GI, and eye health. Competes with Searchlight in several therapeutic areas (e.g., dermatology) and operates in the same Canadian market at much greater scale.

Emerging players

• TherapeuticsMD: U.S. women's health company with branded products in menopause, contraception, and vaginal health. Directly overlaps with Searchlight's women's health franchise (menopause, contraception, Addyi HSDD adjacency).

Regional players

• Theratechnologies: Canadian specialty pharma commercializing in-licensed and proprietary products in women's health/endocrinology and other specialty areas. Comparable Canadian specialty platform focused on differentiated branded products.

Others

• Apotex Inc. Parent company of Searchlight Pharma since June 2024 and Canada's largest pharmaceutical company with generics, biosimilars, and branded products. Corporate parent and now-distribution partner; included as ecosystem participant rather than direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aralez Pharmaceuticals